Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19071345 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | March 2025 | October 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 19026516 | ERGOTHIONEINE-PRODUCING ENGINEERED BACTERIA AND CONSTRUCTION METHOD AND USE THEREOF | January 2025 | October 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18977534 | STRAINS AND METHODS FOR THE CONTINUOUS PRODUCTION OF PRODUCTS BY GAS FERMENTATION | December 2024 | March 2026 | Abandon | 15 | 1 | 1 | No | No |
| 18655606 | ENGINEERED HUMAN EXTRACELLULAR DNASE ENZYMES FOR DRUG CANDIDATE SELECTION | May 2024 | March 2026 | Abandon | 22 | 0 | 1 | No | No |
| 18276657 | BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS AND USE THEREOF | August 2023 | October 2025 | Allow | 26 | 2 | 0 | Yes | No |
| 18325252 | NOVEL ASPERGILLUS ORYZAE STRAIN AND USE THEREOF | May 2023 | December 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18037299 | METHOD AND DRUG FOR INCREASING BDNF LEVEL | May 2023 | March 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18317144 | METHOD OF ENZYMATICALLY PREPARING N-3 POLYUNSATURATED FATTY ACID DIACYLGLYCEROL | May 2023 | August 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18300194 | MOISTURE INDUCED BIOLUMINESCENT COMPOSITION AND METHODS FOR MANUFACTURING THEREOF | April 2023 | September 2025 | Abandon | 29 | 3 | 1 | No | No |
| 18189272 | TRANSFORMANT FOR PRODUCING DODECANEDIOIC ACID AND METHOD FOR PRODUCING DODECANEDIOIC ACID | March 2023 | January 2025 | Allow | 22 | 3 | 0 | No | No |
| 18180507 | NOVEL METHOD FOR PREPARING POLY(3-HYDROXYBUTYRATE-CO-HYDROXYBUTYRATE) | March 2023 | July 2025 | Allow | 28 | 3 | 1 | Yes | No |
| 18117082 | ENGINEERED ENZYMES AND BIOPRODUCTION OF BAKUCHIOL | March 2023 | September 2024 | Allow | 18 | 1 | 1 | No | No |
| 18161794 | METHODS FOR PRODUCTION OF AMYELOIS TRANSITELLA PHEROMONE PRECURSOR | January 2023 | February 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18068418 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | December 2022 | June 2024 | Allow | 18 | 1 | 1 | No | No |
| 18068218 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | December 2022 | June 2024 | Allow | 18 | 1 | 1 | No | No |
| 18068443 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | December 2022 | July 2024 | Allow | 19 | 1 | 1 | No | No |
| 18068327 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | December 2022 | July 2024 | Allow | 19 | 1 | 1 | No | No |
| 18066960 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | December 2022 | June 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 18064886 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | December 2022 | May 2024 | Allow | 17 | 1 | 1 | No | No |
| 18060193 | GENE EDITING SYSTEM FOR EDITING THE ARYLSULFATASE A (ARSA) GENE | November 2022 | July 2024 | Allow | 20 | 1 | 1 | No | No |
| 18071024 | PRODUCTION OF FUNGAL BIOMASS FROM SIMPLE CARBON SOURCES | November 2022 | March 2025 | Abandon | 28 | 2 | 0 | No | No |
| 18070554 | HIGHER PERFORMANCE PROTEASES FOR SCARLESS PEPTIDE TAG REMOVAL | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17907278 | METHOD FOR PRODUCING PHA USING SEA WATER | September 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17951849 | CHIMERIC POLYPEPTIDES HAVING TARGETED BINDING SPECIFICITY | September 2022 | March 2026 | Allow | 42 | 1 | 1 | No | No |
| 17789977 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | June 2022 | October 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17787955 | CHIMERIC DNA POLYMERASE AND APPLICATION THEREOF | June 2022 | March 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17776490 | MODIFIED KLENOW FRAGMENT AND APPLICATION THEREOF | May 2022 | September 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17736396 | METHOD FOR PRODUCING BONE GELATINE, AND PRODUCED BONE GELATINE | May 2022 | April 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17773667 | MICROBIAL DETECTION PLATFORM | May 2022 | August 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17773403 | MEDICAL COMPOSITIONS AND THEIR USE IN TREATING PANCREATIC CANCER | April 2022 | August 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17769630 | METHOD FOR PRODUCING FUSION PROTEIN OF SERUM ALBUMIN AND GROWTH HORMONE | April 2022 | December 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17767764 | BIOSYNTHESIS OF CANNABINOIDS FROM CANNABIGEROLIC ACID USING NOVEL CANNABINOID SYNTHASES | April 2022 | August 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17767033 | SARS-COV-2 RECOMBINANT N PROTEIN, AND PREPARATION METHOD AND PURIFICATION METHOD THEREFOR | April 2022 | March 2026 | Abandon | 47 | 2 | 1 | No | No |
| 17764354 | PEPTIDE PURIFICATION FORMULATIONS AND METHODS | March 2022 | February 2026 | Allow | 47 | 2 | 1 | No | No |
| 17764127 | THERAPEUTIC EFFICACY BY PULMONARY DELIVERY OF LIVE ATTENUATED MYCOBACTERIA | March 2022 | December 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17640307 | DELIVERY VEHICLE FOR IN SITU DELIVERING OF PHARMACEUTICAL AGENTS | March 2022 | August 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17633517 | METHOD FOR CULTURING DERMAL PAPILLA CELLS | February 2022 | February 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17632819 | NUCLEIC ACIDS, PROTEINS AND PROCESSES FOR PRODUCING AMIDES | February 2022 | December 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17631162 | METHODS AND KITS FOR IDENTIFYING THROMBUS ORIGIN AND OPTIMIZING POST-ISCHEMIC EVENT TREATMENT | January 2022 | September 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17587253 | Compositions and Methods for Treating Pathological Calcification and Ossification | January 2022 | November 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17582548 | ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOF | January 2022 | January 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17626822 | METHOD FOR THE PRODUCTION OF AN ENZYMATIC COMPOSITION COMPRISING A RECOMBINANT ENDOPEPTIDASE | January 2022 | October 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17626665 | METHOD FOR EVALUATING ANTIBIOTIC SUSCEPTIBILITY | January 2022 | March 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17626561 | 3' UTR CRISPR-DCAS 13 ENGINEERING SYSTEM AND METHODS OF USING SAME | January 2022 | July 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17625727 | A recombinant protein produced from cholinesterase gene derived from Pseudomonas aeruginosa and the composition comprising the same for treating or preventing a neurological disease | January 2022 | February 2025 | Allow | 38 | 1 | 0 | No | No |
| 17597306 | SERPIN PRODUCTION | December 2021 | February 2026 | Allow | 50 | 4 | 1 | Yes | No |
| 17597012 | NOVEL LACTIC ACID BACTERIUM DERIVED FROM AMUR CORK LIVING IN SHIRAKAMI MOUNTAINS | December 2021 | December 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17618938 | METHODS OF PROTEIN EXTRACTION AND DOWNSTREAM PROCESSING OF EUGLENA | December 2021 | February 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17606263 | COLANIC ACID PRODUCTION USING MUTANT E. COLI | December 2021 | June 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17614648 | ASSISTANT AGENT FOR ASSISTING INTRODUCTION INTO LIVING BODY AND METHOD OF UTILIZING THE SAME | November 2021 | November 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17611972 | IMPROVED DELIVERY OF GENE THERAPY VECTORS TO RETINAL CELLS USING A GLYCOSIDE HYDROLASE ENZYME | November 2021 | September 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17609113 | PROBIOTICS FOR MENTAL HEALTH | November 2021 | January 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17607371 | METHOD FOR ASYMMETRICALLY PREPARING L-PHOSPHINOTHRICIN BY OXIDATION-REDUCTION REACTION THROUGH BIOLOGICAL MULTI-ENZYME COUPLING | October 2021 | September 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17605120 | ENGINEERED TRANS-ENOYL COA REDUCTASE AND METHODS OF MAKING AND USING | October 2021 | February 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17605196 | ENGINEERED MICROORGANISMS AND METHODS FOR IMPROVED ALDEHYDE DEHYDROGENASE ACTIVITY | October 2021 | November 2025 | Allow | 49 | 2 | 1 | No | No |
| 17604417 | CIRCULARLY PERMUTATED HALOALKANE TRANSFERASE FUSION MOLECULES | October 2021 | March 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17601802 | USING SYNTHETIC LIXIVIANT BIOLOGY FOR THE RECOVERY OF PRECIOUS AND TOXIC METALS FROM ANTHROPOGENIC SOURCES | October 2021 | July 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17601197 | IMPROVEMENT OF AFFINITY CHROMATOGRAPHY OF IMMUNOGLOBULINS BY USING PRE-CAPTURE FLOCCULATION | October 2021 | December 2025 | Allow | 50 | 2 | 0 | Yes | Yes |
| 17600927 | FUNGAL EXTRACTS AND FLAVOR COMBINATIONS THEREOF | October 2021 | February 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17601052 | NOVEL NUCLEIC ACID MODIFIERS | October 2021 | August 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17600276 | PROCESS FOR THE PURIFICATION OF RECOMBINANT POLYPEPTIDES | September 2021 | February 2026 | Abandon | 53 | 3 | 1 | No | No |
| 17442675 | Amylase Enzymes | September 2021 | December 2025 | Allow | 50 | 2 | 1 | No | No |
| 17435709 | Artificial Fusion of Dehydratase Enzymes to Improve Production of Fatty Acids | September 2021 | September 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17435695 | PRODUCTION OF CANNABINOIDS USING GENETICALLY ENGINEERED PHOTOSYNTHETIC MICROORGANISMS | September 2021 | October 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17430013 | LACHNOSPIRACEAE BACTERIUM ND2006 CAS12A MUTANT GENES AND POLYPEPTIDES ENCODED BY SAME | August 2021 | November 2024 | Allow | 39 | 2 | 1 | No | No |
| 17429493 | METHOD FOR CONTINUOUS PRODUCTION OF RECOMBINANT GLP-1 PEPTIDE BY BACTERIA | August 2021 | August 2024 | Allow | 36 | 2 | 0 | No | No |
| 17427974 | ENGINEERED HUMAN EXTRACELLULAR DNASE ENZYMES FOR DRUG CANDIDATE SELECTION | August 2021 | September 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17389026 | ENHANCEMENT OF HYDRATION AND IMPROVEMENT IN GUT HEALTH THROUGH CLOACAL DELIVERY OF PRODUCTS | July 2021 | December 2025 | Allow | 53 | 2 | 0 | No | No |
| 17372406 | NOVEL NUCLEIC ACID MODIFIERS | July 2021 | March 2026 | Abandon | 56 | 2 | 1 | No | No |
| 17421243 | MODIFIED FIBROIN | July 2021 | March 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17418319 | LIQUID COMPOSITION COMPRISED OF A MICELLAR CASEIN CONCENTRATE | June 2021 | August 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17416143 | Method for Filtering Fibrinogen | June 2021 | October 2025 | Allow | 52 | 3 | 0 | Yes | No |
| 17311771 | COMPOSITION FOR PROMOTING GROWTH OF EFFECTIVE MICROORGANISM AND CONTROLLING PLANT DISEASE USING PREBIOTICS, AND USE THEREOF | June 2021 | June 2024 | Allow | 36 | 2 | 0 | No | No |
| 17296559 | METHOD FOR PREPARATION OF PRIMARY AMINE COMPOUNDS | May 2021 | February 2025 | Abandon | 45 | 2 | 0 | Yes | No |
| 17327586 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | May 2021 | May 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17293230 | MICROBIAL CELLS AND METHODS FOR PRODUCING CANNABINOIDS | May 2021 | July 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17242116 | Crystal Structure of a Replication Protein encoded by a Plasmid isolated from a Multiple Sclerosis Patient | April 2021 | November 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17250769 | A DOUBLE PEPTIDE TAG COMBINING REVERSIBILITY AND FLEXIBLE FUNCTIONALIZATION | March 2021 | June 2025 | Abandon | 52 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCKNIGHT, CIARA A.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MCKNIGHT, CIARA A works in Art Unit 1656 and has examined 33 patent applications in our dataset. With an allowance rate of 48.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner MCKNIGHT, CIARA A's allowance rate of 48.5% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MCKNIGHT, CIARA A receive 1.48 office actions before reaching final disposition. This places the examiner in the 25% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MCKNIGHT, CIARA A is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +63.6% benefit to allowance rate for applications examined by MCKNIGHT, CIARA A. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 71% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 53.3% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 12.5% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.